No hantavirus vaccine is on track for U.S. Food and Drug Administration approval by the end of 2026, as all candidates remain in preclinical testing or early Phase 1 human trials with no Phase 3 efficacy studies underway. Official data from the CDC and WHO confirm ongoing transmission via rodent exposure, with a recent multi-country cluster of eight cases and three deaths linked to cruise ship travel underscoring the public health need but not accelerating regulatory timelines. Research at institutions like the University of Bath and collaborators focuses on mRNA and DNA platforms targeting strains such as Andes or Hantaan, yet experts note that standard safety and efficacy requirements, compounded by the virus's low incidence, typically demand five to ten years for full licensure absent emergency funding comparable to Operation Warp Speed. Trader consensus at 90% for no approval reflects these established clinical development barriers.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$88,849 Vol.
$88,849 Vol.
31 dez 2026
$88,849 Vol.
$88,849 Vol.
31 dez 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is on track for U.S. Food and Drug Administration approval by the end of 2026, as all candidates remain in preclinical testing or early Phase 1 human trials with no Phase 3 efficacy studies underway. Official data from the CDC and WHO confirm ongoing transmission via rodent exposure, with a recent multi-country cluster of eight cases and three deaths linked to cruise ship travel underscoring the public health need but not accelerating regulatory timelines. Research at institutions like the University of Bath and collaborators focuses on mRNA and DNA platforms targeting strains such as Andes or Hantaan, yet experts note that standard safety and efficacy requirements, compounded by the virus's low incidence, typically demand five to ten years for full licensure absent emergency funding comparable to Operation Warp Speed. Trader consensus at 90% for no approval reflects these established clinical development barriers.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercado Aberto: May 4, 2026, 10:39 AM ET
Volume
$88,849Data de Término
31 dez 2026Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is on track for U.S. Food and Drug Administration approval by the end of 2026, as all candidates remain in preclinical testing or early Phase 1 human trials with no Phase 3 efficacy studies underway. Official data from the CDC and WHO confirm ongoing transmission via rodent exposure, with a recent multi-country cluster of eight cases and three deaths linked to cruise ship travel underscoring the public health need but not accelerating regulatory timelines. Research at institutions like the University of Bath and collaborators focuses on mRNA and DNA platforms targeting strains such as Andes or Hantaan, yet experts note that standard safety and efficacy requirements, compounded by the virus's low incidence, typically demand five to ten years for full licensure absent emergency funding comparable to Operation Warp Speed. Trader consensus at 90% for no approval reflects these established clinical development barriers.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$88,849Data de Término
31 dez 2026Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No hantavirus vaccine is on track for U.S. Food and Drug Administration approval by the end of 2026, as all candidates remain in preclinical testing or early Phase 1 human trials with no Phase 3 efficacy studies underway. Official data from the CDC and WHO confirm ongoing transmission via rodent exposure, with a recent multi-country cluster of eight cases and three deaths linked to cruise ship travel underscoring the public health need but not accelerating regulatory timelines. Research at institutions like the University of Bath and collaborators focuses on mRNA and DNA platforms targeting strains such as Andes or Hantaan, yet experts note that standard safety and efficacy requirements, compounded by the virus's low incidence, typically demand five to ten years for full licensure absent emergency funding comparable to Operation Warp Speed. Trader consensus at 90% for no approval reflects these established clinical development barriers.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions